Objective: Dysregulation of maternal circulating adipokines has been implicated in several ''great obstetrical syndromes'' including preeclampsia (PE), small-for-gestational age (SGA) neonate and fetal death (FD). It has been suggested that adipokines provide a molecular link between metabolic derangements and inflammatory response in complicated pregnancies. Retinol binding protein 4 (RBP4), a novel adipokine, plays a role in obesity-related disorders, as well as in the regulation of the immune response. The aim of this study was to determine whether there are changes in maternal plasma concentrations of RBP4 in patients with PE and in those with an SGA neonate or FD. Study design: This cross-sectional study included patients in the following groups: 1) normal pregnancy (ns134); 2) PE (ns104); 3) SGA neonate (ns28); and 4) FD (ns 37). Maternal plasma RBP4 concentrations were determined by ELISA. Non-parametric statistics were used for analysis. Results: 1) The median maternal plasma RBP4 concentration was higher among patients with PE than in those with a normal pregnancy (Ps0.03); 2) The median maternal plasma RBP4 concentrations of patients with preterm PE (-37 weeks) was higher than that of those with term PE (Ps0.017) and than that of those with a normal pregnancy (Ps0.002); 3) The median maternal plasma RBP4 concentration did not differ significantly between patients with a normal pregnancy and those with an SGA neonate or with an FD; 4) Among normal pregnant women, the maternal plasma RBP4 concentrations did not correlate with pre-pregnancy body mass index, gestational age at blood sampling and neonatal birthweight. Conclusions: 1) Preeclampsia, but not pregnancy with an SGA neonate or an FD, is associated with a higher median maternal plasma concentration of RBP4 than normal pregnancy; 2) Preterm PE, and specifically early-onset PE, is associated with higher median RBP4 concentrations in maternal plasma compared to term PE. These findings suggest a role for RBP4 in the pathogenesis of preterm PE, but not in SGA and FD.
Introduction
Preeclampsia is a leading cause of maternal and perinatal mortality and morbidity w27, 61, 106, 110x, and together with small-for-gestational age (SGA) neonate and fetal death (FD) are part of the ''great obstetrical syndromes'' w102x. Consistent with the syndromic nature of these conditions, several mechanism of disease have been associated with their clinical manifestations, such as an anti-angiogenic state w17, 18, 30, 31, 38, 57, 59, 60, 65, 103, 122, 126x , abnormal physiologic transformation of the spiral arteries w14, 15, 26, 83, 91x, chronic uteroplacental ischemia w12, 41, 85, 100, 108x , increased trophoblast apoptosis/necrosis w51x and endothelial cell dysfunction w22, 36, 92, 97, 99, 119x . Notably, preeclampsia, SGA and FD have all been associated with maternal metabolic complications such as obesity w23, 29, 110, 111, 129x, insulin resistance w34, 52, 115, 131x and dyslipidemia w42, 128x. In addition, these women have an increased risk of metabolic syndrome-related morbidity w20, 39, 44, 109x and mortality w49, 53, 113x later in life.
Adipokines are a family of biologically active adipocytederived cytokines/hormones, such as leptin, adiponectin, visfatin and resistin, as well as tumor necrosis factor (TNF), interleukin (IL)-6, IL-1 and monocyte chemotactic protein-1 (MCP-1) w120x. Adipokines have been implicated in the physiology and pathophysiology of glucose homeostasis, providing a link between obesity, insulin resistance and type 2 diabetes mellitus (DM) w120x. In addition, adipocytokines play a role in the pathophysiology of inflammatory disorders such as asthma w43x, inflammatory bowel disease w6, 123x, rheumatoid arthritis w10, 105x and obesity w32, 121, 132, 133x. Alterations in circulating concentrations of adipokines such as leptin, adiponectin, visfatin and TNF-a have been associated with the pathogenesis of preeclampsia w24, 25, 45, 64, 79, 86, 95x , SGA w72, 81x and FD w89x, as well as other complications of pregnancy w58, 68-71, 73-78, 80, 82, 87, 88, 125x. Retinol binding protein 4 (RBP4), previously thought to be only a specific carrier for retinol and be produced mainly by the liver, has recently w132x been added to the rapidly expanding family of adipokines. RBP4 is suggested to have a role in obesity-induced insulin resistance and, like other adipokines, increased circulating RBP4 concentrations have been reported in patients with diabetes w132x as well as in those destined to develop overt diabetes w21, 40x. Thus, lowering RBP4 concentrations has been suggested as a potential therapeutic target in type 2 DM w40, 118, 132x. Furthermore, RBP4 may play a role in inflammation w5, 134x. Indeed, in non-diabetic human subjects, RBP4 gene expression was found to be strongly associated with inflammatory markers of adipose tissue such as CD68 and MCP-1 w134x.
Currently, there is only one report w117x of RBP4 concentrations in patients with preeclampsia which found no association between maternal circulating concentrations of RBP4 and preeclampsia. Moreover, there are no data regarding changes in circulating RBP4 in patients with SGA or FD. The aim of this study was to determine whether maternal plasma concentration of RBP4 is associated with preeclampsia, delivery of an SGA neonate or an FD.
Materials and methods

Study groups and inclusion criteria
A retrospective cross-sectional study was conducted comprising women in the following groups: 1) normal pregnant women (ns134); 2) patients with preeclampsia (ns104); 3) pregnant women without preeclampsia or hypertension who delivered an SGA neonate (ns28); and 4) patients without preeclampsia or hypertension who had an FD (ns37). Women with multiple pregnancies or fetuses with congenital and/or chromosamal anomalies were excluded.
Samples and data were retrieved from our bank of biological samples and clinical databases. Many of these samples have previously been used to study the biology of inflammation, hemostasis, and angiogenesis regulation in normal pregnant women and those with pregnancy complications.
All participants provided written informed consent prior to the collection of maternal blood. The collection of maternal blood and its use for research purposes was approved by the Institutional Review Boards of the Sotero del Rio Hospital (Chile), Wayne State University (Detroit, Michigan, USA) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD/NIH/DHHS).
Clinical definitions
Women with a normal pregnancy were defined as those without medical, obstetrical, or surgical complications at the time of the study and who subsequently delivered at term ()37 weeks of gestation) an appropriate-for-gestational age infant w3x, without neonatal complications. Preeclampsia was defined as the onset of hypertension (systolic blood pressure G140 mm Hg and/or diastolic blood pressure G90 mm Hg on at least two occasions, 4 h to 1 week apart) after 20 weeks of gestation with proteinuria (G300 mg in a 24 h urine collection or at least one dipstick measurement G2q) w1x. Severe preeclampsia was diagnosed according to the criteria proposed by the American College of Obstetricians and Gynecologists (ACOG) committee w1x. Preterm preeclampsia was defined as the development of preeclampsia before 37 completed weeks of gestation. Patients with preeclampsia were further classified as either having early-onset (-32 weeks), or late-onset (G32 weeks) disease according to the gestational age at which preeclampsia was diagnosed. SGA was defined as birthweight below the 10 th percentile w3x. Women with an FD included those with a singleton pregnancy and FD diagnosed after 20 weeks of gestation. FD was determined by absence of heart motion on ultrasound examination. The body mass index (BMI) was calculated using the formula: weight (kg)/height (m 2 ). The study population was classified according to the pre-pregnancy BMI into two groups: normal weight (BMI -25 kg/m 2 ) and overweight/obese (BMI G25 kg/m 2 ) women w2x.
Sample collection and determination of RBP4 in maternal plasma
Maternal blood samples were obtained once from each woman at the time of diagnosis and collected in vials containing ethylenediaminetetraacetic acid. The samples were then centrifuged at 1300=g for 10 min at 48C and the obtained plasma was stored at -808C until assayed. Maternal plasma concentration of RBP4 was determined by sensitive enzyme-linked immunoassays (Millipore Corporation, St. Charles, MO, USA). The RBP4 immunoassay was validated for human plasma in our laboratory, prior to the conduction of this study. Immunoassays were carried out according to the manufacturer's recommendations. The calculated inter-and intraassay coefficients of variation for RBP4 immunoassays in our laboratory were 5% and 5.1%, respectively. The sensitivity was calculated to be 0.10 ng/mL.
Statistical analysis
Normality of the data was tested using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Since maternal plasma RBP4 concentrations were not normally distributed, Kruskal-Wallis test with post-hoc analysis by Mann-Whitney U-test were used for comparisons of continuous variables. Comparison of proportions was performed using x 2 or Fisher's exact tests. Correlations between RBP4 concentrations and pre-pregnancy BMI and gestational age at blood sampling were examined using Spearman's rank correlation test. A P-0.05 was considered statistically significant. Analysis was performed with SPSS, version 14 (SPSS Inc., Chicago, IL, USA).
Results
Demographic and clinical characteristics of women with a normal pregnancy, preeclampsia, an SGA neonate and an FD are listed in Table 1 . Compared to women with a normal pregnancy, patients with pre-eclampsia had a higher rate of nulliparity, women with an SGA neonate were more likely to smoke and to have a lower pre-pregnancy BMI, and those Values are expressed as median (interquartile range) or % (number). P 1 sbetween preeclampsia and normal pregnancy, P 2 sbetween SGA and normal pregnancy, P 3 sbetween FD and normal pregnancy. PEspreeclampsia, SGAssmall-for gestational age, FDsfetal death, BMIsbody mass index, NSsnot significant.
with an FD had a lower median gestational age at blood sampling. All three groups had a lower median gestational age at delivery and a lower median neonatal birthweight than women with a normal pregnancy.
Maternal plasma RBP4 concentration in normal pregnancy
RBP4 was detected in the maternal plasma of all subjects included in this study. Among women with a normal pregnancy, maternal plasma RBP4 concentration did not correlated with pre-pregnancy BMI (Spearman's r -0.64, Ps0.6), gestational age at blood sampling (Spearman's r -0.038, Ps0.7) or neonatal birthweight (Spearman's r -0.032, Ps0.8). In addition, the median maternal plasma RBP4 concentration did not differ significantly between women with a normal BMI and overweigh/obese women (median 9025.5 ng/mL, IQR 7681.9-10811 vs. 9023.4 ng/mL, IQR 7272.0-10506.7, respectively; Ps0.8). Similarly, there was no significant difference between women who smoked and those who did not (median 8102.5 ng/mL, IQR 7090.3-10332.8 vs. 9168.8 ng/mL, IQR 7602.9-10245.9, respectively; Ps0.3).
Maternal plasma RBP4 concentration in patients with preeclampsia
The median maternal plasma RBP4 concentration was higher in women with preeclampsia than in those with a normal pregnancy (9769.3 ng/mL vs. 9080.9 ng/mL, Ps0.03; Figure  1 ). In patients with pre-eclampsia, the maternal plasma RBP4 concentrations correlated with gestational age at blood sampling (Spearman's r -0.34, P-0.001) and neonatal birthweight (Spearman's r -0.31, Ps0.01, but not with pre-pregnancy BMI (Spearman's r -0.03, Ps0.77). The median maternal plasma RBP4 concentration did not differ significantly between women with a normal BMI and overweight/obese women with preeclampsia (9888.4 ng/mL vs. 9932.2 ng/mL, respectively; Ps0.9).
RBP4 in preterm preeclampsia (-37 weeks' gestation)
Among patients with preeclampsia, 37% (39/104) had preterm preeclampsia. The median maternal plasma RBP4 concentration of these women was higher than that in those with preeclampsia at term (10257.6 ng/mL vs. 9018.3 ng/mL, Ps0.017; Figure 2) . Similarly, patients with preterm preeclampsia had a higher median RBP4 concentration than women with a normal pregnancy (10257.6 ng/mL vs. 9080.9 ng/mL, Ps0.002; Figure 2 ). There was no significant difference in the median maternal plasma RBP4 concentration between women with term preeclampsia and those with a normal pregnancy (Ps0.8, Figure 2 ).
RBP4 in early-onset preeclampsia (-32 weeks' gestation)
Early-onset preeclampsia (-32 weeks' gestation) was diagnosed in 27% (28/104) of patients with preeclampsia. The demographic and clinical characteristics of women with early and late-onset preeclampsia (G32 weeks' gestation) are displayed in Table 2 . The median maternal plasma RBP4 concentration of women with early-onset preeclampsia was higher than in those diagnosed with preeclampsia at Figure 1 Box and whisker plot of the comparison of the median plasma RBP4 concentrations of women with a normal pregnancy and those with preeclampsia, SGA or FD. The median maternal plasma concentration of RBP4 was higher in patients with preeclampsia than in those with a normal pregnancy (9769.3 ng/mL, interquartile range (IQR) 7780.2-11732.8 vs. 9080.9 ng/mL, IQR 7284.4-10741.3, Ps0.03). The median maternal plasma concentration of RBP4 was not significantly different between patients with a normal pregnancy (9080.9 ng/mL, IQR 7284.4-10741.3), those with an SGA neonate (8831.3 ng/mL, IQR 7223.9-10056.1, Ps0.6) and pregnant women with an FD (8877.3 ng/mL, IQR 7730.4-10878.9, Ps0.7).
Figure 2
Box and whisker plot of the comparison of the median maternal plasma RBP4 concentration of patients with preterm (-37 weeks gestation) and term preeclampsia. The median maternal plasma RBP4 concentration among women with preterm preeclampsia was higher than in patients with a normal pregnancy (10257.6 ng/mL, IQR 8690.4-12500.4 vs. 9080.9 ng/mL, IQR 7284.4-10741.3, Ps0.002), as well as those with term pre-eclampsia (9018.3 ng/mL, IQR 7451.4-10768.7, Ps0.017). The median RBP4 concentration in maternal plasma did not differ significantly between normal pregnant women and those with term preeclampsia (Ps0.8).
G32 weeks of gestation (11427 ng/mL vs. 9260.0 ng/mL, P-0.001; Figure 3 ), as well as than in women with a normal pregnancy (11427 ng/mL, vs. 9080.9 ng/mL, P-0.001; Figure 3) . In contrast, the median maternal plasma RBP4 concentration did not differ significantly between patients with preeclampsia diagnosed G32 weeks of gestation and normal pregnant women (Ps0.8).
RBP4 in severe preeclampsia and preeclampsia with an SGA neonate
Among patients with preeclampsia, 80% (83/104) had severe preeclampsia, and 49% (51/104) delivered an SGA neonate. There was no significant difference in the median maternal plasma concentration of RBP4 between patients with severe preeclampsia and those with mild preeclampsia (9810.9 ng/mL, IQR 7816.1-11715.7 vs. 9724.7 ng/mL, IQR 7699.4-11754.2, respectively; Ps0.7). Similarly, the median maternal plasma RBP4 concentration did not differ significantly between patients with preeclampsia with or without an SGA neonate (9721.6 ng/mL, IQR 8249.3-12393.2 vs. 9837.5 ng/mL, IQR 7603.4-11698.4, respectively; Ps0.6).
Maternal plasma RBP4 in patients with an SGA neonate or an FD Among normotensive women with an SGA neonate, 82% (23/28) had a neonate with a birthweight -5 th centile for gestational age. The median maternal plasma concentration of RBP4 was not significantly different between women with an SGA neonate and those with a normal pregnancy (8831.3 ng/mL vs. 9080.9 ng/mL, respectively; Ps0.6; Figure 1) . There was no significant difference in the median maternal plasma RBP4 concentration of women with severe SGA (-5 th centile for gestational age) and those whose neonates weighed between the 5 th and -10 th centiles for gestational age (8938.3 ng/mL, IQR 7112.6-10328.8 vs. 7818.0 ng/mL, IQR 7079.7-9833.9, respectively; Ps0.5).
Similarly, the median maternal plasma RBP4 concentrations did not differ significantly between women with an FD and those with a normal pregnancy (8877.3 ng/mL vs. 9080.9 ng/mL, respectively; Ps0.7; Figure 1 ).
Discussion
Principal findings of the study 1) Patients with preeclampsia had a higher median maternal plasma concentration of RBP4 than women with a normal Box and whisker plot of the comparison of the median maternal plasma RBP4 concentration of patients with early-onset preeclampsia (-32 weeks' gestation) and those with preeclampsia diagnosed G32 weeks' gestation. The median maternal plasma RBP4 concentration of patients with early-onset preeclampsia was higher than in women with a normal pregnancy (11427 ng/mL, IQR 9852.9-13560.0 vs. 9080.9 ng/mL, IQR 7284.4-10741.3, P-0.001) and than those with preeclampsia diagnosed G32 weeks' gestation (9260.0 ng/mL, IQR 7456.0-10880.9, P-0.001). The median RBP4 concentration in maternal plasma did not differ significantly between normal pregnant women and those with preeclampsia diagnosed G32 weeks' gestation (Ps0.8).
pregnancy; 2) Early-onset preeclampsia (-32 weeks) is associated with a higher median maternal plasma RBP4 concentration than late-onset preeclampsia; 3) The median maternal plasma RBP4 concentrations of women with an SGA neonate or FD did not differ significantly from normal pregnant women.
RBP4 -a novel adipokine
Retinol binding protein w55x belongs to the lipocalin family and is a specific carrier of retinol from the liver to peripheral tissues. RBP4 is a plasma protein w101x, while RBP1, RBP2 w28x, RBP5 and RBP7 are cellular proteins, and RBP3 is the interstitial form w62x.
Although RBP is mainly synthesized by the liver w93x, subsequent studies demonstrated that it is also produced by adipocytes w66, 84x. Only recently, RBP4 has been characterized as a novel adipokine when its role in the pathogenesis of insulin resistance has been proposed w132x. RBP4, similar to other adipokines w11, 58, 63, 73-75, 86-88, 112, 120, 121, 132, 133x , has also been linked to inflammation w5, 134x. Gene expression of RBP4 was found to be strongly associated with inflammatory markers (i.e., CD68 and MCP-1) of adipose tissue in non-diabetic human subjects w134x. In children, RBP4 concentrations correlated not only with indices of obesity and insulin resistance but also with inflammatory factors such as C-reactive protein and IL-6 w5x.
RBP4 concentration during normal gestation
Among women with a normal pregnancy, there was no correlation between RBP4 concentrations and maternal age, gestational age at blood sampling, pre-pregnancy BMI and neonatal birthweight. In addition, there was no difference in the median RBP4 concentrations between normal weight and overweight/obese patients, as well as between healthy pregnant women who smoked and those who did not.
Our findings are in agreement with a recent report by Stepan et al. w117x in which RBP4 was not associated with gestational age at blood sampling, gestational age at delivery and neonatal birthweight. The authors also reported a lack of correlation between RBP4 and markers of adiposity (BMI, leptin), insulin resistance (fasting glucose, fasting insulin, HOMA-IR and adiponectin) and lipid metabolism (cholesterol, triglycerides) w117x. Similarly, no change in circulating RBP with increasing gestational age was reported w7, 19, 35, 37x. The results of our study demonstrate lack of correlation over a wide range of gestational age (20-42 weeks' gestation) and that there is no difference in RBP4 concentrations between normal weight and overweight/obese pregnant women.
RBP4 concentration is elevated in preterm preeclampsia but not in term preeclampsia
The finding that the median maternal plasma concentration of RBP4 is higher in patients with preeclampsia than in women with a normal pregnancy is novel. Moreover, among patients with preeclampsia, but not in normal pregnant women, the RBP4 concentrations had a significantly negative correlation with gestational age at blood collection (at the time of diagnosis of pre-eclampsia). Thus, the earlier the diagnosis, the higher was the maternal plasma RBP4 concentrations. This is pertinent since the timing of the diagnosis of preeclampsia is an important index of severity. The finding that preeclampsia is associated with higher circulating RBP4 concentrations is in agreement with a recent study by Atkinson et al. w4x in which a proteomic approach was used to identify novel biomarkers for preeclampsia. The authors found RBP4 to be differentially up-regulated (2.1-fold change) in the serum of patients with preeclampsia compared to matched healthy pregnant women w4x.
Our results are in disagreement with the study reported by Stepan et al. w117x regarding RBP4 concentrations in maternal circulation. The authors found no significant differences in the mean maternal serum RBP4 concentration between patients with preeclampsia (ns16) compared to normotensive controls (ns20) admitted to the hospital for other obstetrical complications w117x. This apparent contradiction can be explained by differences in sample size, study population and inclusion criteria for the control group. In addition, the authors w117x did not differentiate between term and preterm preeclampsia. The relatively large sample size of our study allowed us to identify higher concentrations of circulating RBP4 in patients with early-onset preeclampsia.
Why is early-onset preeclampsia associated with elevated maternal RBP4 concentrations?
The cross-sectional nature of our study does not allow us to discern a cause-effect relationship between elevated maternal plasma RBP4 concentrations and preeclampsia; however, several suggestions for this finding can be raised:
1. An activation of the immune response has been implicated as a cause of endothelial cell dysfunction and preeclampsia w36, 97, 99x. Adhesion molecules play a central role in the adherence of leukocytes to endothelial cells and the subsequent migration of white blood cells into perivascular tissue and have been implicated in the pathophysiology of preeclampsia w16x. A recent study w90x in adults with newly diagnosed type 2 DM reported a positive correlation between RBP4 and soluble adhesion molecules such as sICAM-1 and sE-selectin. It was suggested that RBP4 might be responsible for up-regulating endothelial adhesion molecules and the development of vascular complications in type 2 DM w8, 56x. Furthermore, RBP4 inhibits insulin action in endothelial cells, leading to impaired NO-dependent vasodilation w127x. Thus, the increased maternal plasma RBP4 concentration in patients with preeclampsia may be an additional marker of endothelial dysfunction w90x. 2. Several hallmarks of the metabolic syndrome, which includes abdominal obesity, high level of triglycerides, low level of high-density lipoprotein, cholesterol, high blood pressure, and high fasting glucose are well established risk factors for preeclampsia w29, 34, 42, 48, 50, 52, 54, 110, 115, 131x . Similar to the metabolic syndrome, preeclampsia is emerging as a risk factor for cardiovascular complications later in life w9, 33, 44, 96, 109, 113, 114, 130x . Importantly, Bellamy et al. w9x reported in a recent meta-analysis that women who had preterm preeclampsia had the greatest risk of future cardiovascular disease, and this was higher than those who had severe preeclampsia, supporting the concept that timing of onset of preeclampsia more accurately reflects the severity of the maternal cardiovascular phenotype w9x. Elevated circulating RBP4 concentration has been linked to insulin resistance w21, 40, 132x, a core component of the metabolic syndrome. Moreover, it has been associated with a subclinical cardiovascular disease in the elderly w47x. Thus, the elevated RBP4 concentration found in patients with early-onset preeclampsia may be a marker for a subclinical metabolic syndrome, which is reflected by the greater risk of cardiovascular complications in later life observed in these women compared to those with term preeclampsia w9x. 3. Serum RBP4 concentration has been shown to be elevated in patients with impaired kidney function w94, 104x. In addition, it has been suggested that the increased RBP concentration observed in patients with type 2 DM may be due to impaired kidney function rather than the diabetic state itself w46, 67x. During normal pregnancy, the urinary excretion of RBP is greater than in the non-pregnant state, and increases from the first to the second and third trimester w7, 35x. It is possible that the impaired renal function that accompanies preeclampsia, especially in its more severe form, may lead to decreased glomerular filtration rate and decreased excretion of RBP4 in urine.
In our study, a significantly higher proportion of patients with early-onset preeclampsia (-32 weeks) had a urine dipstick measurement G3q protein compared to those diagnosed with preeclampsia later in pregnancy (86% w24/28x vs. 64% w49/76x, Ps0.03). 4. The lack of correlation between circulating RBP4 concentrations and obesity-related parameters demonstrated in our study and those of others w117, 124x, leads to the suggestion that the liver, rather than adipose tissue, may be involved in regulating the circulating RBP4 concentration w13x. It may be that the differences in the RBP4 concentration between normal pregnant women and those with early-onset preeclampsia are related to liver dysfunction. Hepatic fat accumulation has been demonstrated to increase RBP4 w107, 116x and a positive association between alanine aminotransferase and RBP4 concentrations has been recently suggested w98x. In our study, there was a trend toward a higher rate of elevated liver function tests (aspartate aminotransferase )70 IU/L) in patients with early-onset preeclampsia than in those with preeclampsia later in pregnancy (23% w6/23x vs. 11% w8/73x, respectively; Ps0.1).
RBP4 concentrations in maternal blood are not associated with SGA or FD
Although preeclampsia, SGA and FD share several common mechanisms of disease, we did not find an association between circulating maternal RBP4 and pregnancies complicated by an SGA infant or an FD. These findings suggest that RBP4 does not play a role in the pathophysiology of these obstetrical syndromes among normotensive pregnant women. The elevated concentrations of RBP4 found only in patients with early-onset preeclampsia could be explained by different mechanisms of disease distinguishing this complication from SGA or FD. While the clinical manifestations of preeclampsia involve mainly the maternal compartment, SGA and FD are primarily a consequence of a fetal disease. Thus, the increased circulating RBP4 concentrations in preeclampsia may reflect an exaggerated maternal inflammatory response, a subclinical metabolic syndrome or other aspects of disease such as renal or liver dysfunction associated with preeclampsia.
In conclusion, we were able to demonstrate, for the first time, an association between higher maternal circulating RBP4 concentration and preeclampsia, specifically among patients with early-onset preeclampsia. Such an association was not evident among normotensive pregnant women with either an SGA neonate or an FD. Further studies are needed in order to elucidate the relationship between maternal circulating RBP4 concentration and preeclampsia. 
